SEC Form 4 · accession 0001723128-19-000019
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd P. Branning
Officer — SVP, Chief Financial Officer
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $12.44 | Jan 22, 2019 | A | 163,666 | A | — | Jan 22, 2029 | Class A Common Stock | 163,666 | 163,666 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 22, 2019 | A | 80,386 | A | — | — | Class A Common Stock | 80,386 | 80,386 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on January 22, 2020.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F3The restricted stock units vest in four equal annual installments beginning on January 22, 2020 and have no expiration date.